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Electrocardiogram ST Analysis During Labor
A Systematic Review and Meta-analysis of Randomized
Controlled Trials
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and Vincenzo Berghella, MD
OBJECTIVE: To compare the effectiveness of cardioto-
cography plus ST analysis with cardiotocography alone
during labor.
DATA SOURCES: Randomized controlled trials were
identified by searching electronic databases.
METHODS OF STUDY SELECTION: We included all
randomized controlled trials comparing intrapartum fetal
monitoring with cardiotocography plus ST analysis with
cardiotocography alone. The primary outcome (ie, peri-
natal composite outcome) was a composite of intra-
partum fetal death, neonatal death, Apgar score 3 or less
at 5 minutes, neonatal seizure, metabolic acidosis
(defined as umbilical arterial pH 7.05 or less, and
extracellular fluid base deficit 12 mmol/L or greater),
intubation for ventilation at delivery, or neonatal
encephalopathy.
TABULATION, INTEGRATION, AND RESULTS: Six ran-
domized controlled trials, which included 26,529 labor-
ing singletons with cephalic presentation at term, were
analyzed. Compared with women who were randomized
to cardiotocography, those who were randomized to ST
analysis and cardiotocography had a similar incidence of
perinatal composite outcome (1.5% compared with
1.6%; relative risk [RR] 0.90, 95% confidence interval
[CI] 0.74–1.10; five studies), neonatal metabolic acidosis
(0.5% compared with 0.7%; RR 0.74, 95% CI 0.54–1.02;
five studies), admission to the neonatal intensive care
unit (5.4% compared with 5.5%; RR 0.99, 95% CI 0.90–
1.10; six studies), perinatal death (0.1% compared with
0.1%; RR 1.71, 95% CI 0.67–4.33; six studies), neonatal
encephalopathy (0.1% compared with 0.2%; RR 0.62,
95% CI 0.25–1.52; six studies), cesarean delivery (13.8%
compared with 14.0%; RR 0.96, 95% CI 0.85–1.08; six
studies), and operative delivery (either cesarean or oper-
ative vaginal delivery) (23.9% compared with 25.1%; RR
0.93, 95% CI 0.86–1.01; six studies).
CONCLUSION: The use of ST analysis during labor as an
adjunct to the standard cardiotocography does not
improve perinatal outcomes or decrease cesarean delivery.
(Obstet Gynecol 2016;127:127–35)
DOI: 10.1097/AOG.0000000000001198
Fetal metabolic acidosis is one of the essential cri-teria to define an intrapartum hypoxic event ac-
cording to the American College of Obstetricians and
Gynecologists.1 It is associated with several short- and
long-term neonatal complications, including cerebral
palsy and death.2,3
Cardiotocography has been developed as a form
of continuous electronic fetal monitoring of heart rate
with the aim of detecting fetal hypoxia during labor
and hence preventing metabolic acidosis. Despite
being the standard for intrapartum management in
the United States, this technique, as a result of its high
false-positive rate, significantly increases the cesarean
and operative vaginal delivery rate and is associated
only with less seizures as neonatal benefit, whereas
perinatal mortality is not affected.4,5 Moreover, the
evaluation of cardiotocography is associated with high
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intra- and interobserver variability.4,6 Given these
shortcomings of cardiotocography, research has
focused on alternatives, or at least techniques that could
decrease the false-positive rate of electronic fetal mon-
itoring, and improve neonatal outcomes such as meta-
bolic acidosis and death. Fetal ST waveform analysis,
based on electrocardiogram changes determined by the
myocardial adaptation to oxygen deficiency, has been
studied combined with cardiotocography in several
randomized trials in the hope to decrease cesarean
delivery rates with contradictory results regarding its
ability to improve cardiotocography effectiveness.7–12
The purpose of this meta-analysis was to compare
the effectiveness of cardiotocography alone or with
additional ST waveform analysis monitoring during
labor to lower the rate of adverse neonatal outcome.
SOURCES
The review protocol was established by two inves-
tigators (G.S., V.B.) before commencement and was
registered with the PROSPERO International Pro-
spective Register of Systematic Reviews (registration
No. CRD42015019421).
Two authors (G.S., V.B.) identified trials by search-
ing independently the electronic databases MEDLINE,
Scopus, ClinicalTrials.gov, the PROSPERO Interna-
tional Prospective Register of Systematic Reviews,
EMBASE, and the Cochrane Central Register of Con-
trolled Trials with the use of a combination of text
words: “ST analysis,” “STAN,” “cardiotocography,”
“intrapartum fetal monitoring,” “CTG,” “randomized
trial,” “metabolic acidosis,” “EFM,” “electrocardio-
gram,” and “labor” from inception of each databases
until August 2015.
STUDY SELECTION
We included all randomized controlled trials (RCTs)
comparing intrapartum electronic fetal monitoring
with cardiotocography plus ST waveform analysis
(STAN group) compared with cardiotocography
alone (control group). Selection included singleton
gestations in cephalic presentation at term or near
term in labor. Randomized trials using PR interval
and not ST waveform analysis were excluded. Studies
in multiple gestations and quasirandomized trials (ie,
trials in which allocation was done on the basis of
a pseudorandom sequence, for example, odd–even
hospital number or date of birth, alternation) were
also excluded.
The risk of bias in each included study was
assessed by using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions.13
Seven domains related to risk of bias were assessed in
each included trial because there is evidence that these
issues are associated with biased estimates of treat-
ment effect: 1) random sequence generation; 2) allo-
cation concealment; 3) blinding of participants and
personnel; 4) blinding of outcome assessment; 5)
incomplete outcome data; 6) selective reporting;
and 7) other bias. Review authors’ judgments were
categorized as “low risk,” “high risk,” or “unclear risk”
of bias.13
Two authors (G.S., V.B.) independently assessed
inclusion criteria, risk of bias, and data extraction.
Disagreements were resolved by consensus through
discussion. Data from each eligible study were ex-
tracted without modification of original data onto
custom-made data collection forms. Differences were
reviewed and further resolved by common review of
the entire process. Data not presented in the original
publications were requested from the principal
investigators.
Primary and secondary outcomes were defined
before data extraction. The primary outcome was
perinatal composite outcome, defined as at least one
of the following: intrapartum fetal death, neonatal
death, Apgar score 3 or less at 5 minutes, neonatal
seizure, metabolic acidosis (defined as umbilical
arterial pH 7.05 or less and extracellular fluid base
deficit 12 mmol/L or greater), intubation for ventila-
tion at delivery, or neonatal encephalopathy. Second-
ary outcomes included incidence of metabolic
acidosis, admission to the neonatal intensive care unit,
perinatal death (ie, either stillbirth or neonatal death),
hypoxic–ischemic encephalopathy, meconium aspira-
tion syndrome, shoulder dystocia, need for fetal blood
sampling, and type of delivery. We planned to assess
the primary outcome in sensitivity analyses according
to the inclusion criteria of the trials and according to
the ST waveform analysis method used.
The data analysis was completed independently by
two authors (G.S., V.B.) using Review Manager 5.3.13
The completed analyses were then compared, and any
difference was resolved with review of the entire data
and independent analysis. Statistical heterogeneity
between studies was assessed using the Higgins I2 sta-
tistic.13 In case of statistically significant heterogeneity
(I2 50% or greater), the random effects model of Der-
Simonian and Laird was used to obtain the pooled risk
estimate; otherwise, a fixed-effects model was utilized.13
The summary measures were reported as relative risk
(RR) with 95% confidence interval (CI) with an RR less
than 1 indicating treatment benefit. P,.05 was consid-
ered statistically significant. Potential publication biases
were assessed graphically by using a funnel plot and
statistically by using Begg’s and Egger’s tests.13
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The meta-analysis was reported following the
Preferred Reporting Item for Systematic Reviews
and Meta-analyses (PRISMA) statement.14
RESULTS
Six RCTs met inclusion criteria for this meta-analysis
and were analyzed (Appendix 1, available online at
http://links.lww.com/AOG/A738).7–12 The overall
risk of bias was low (Fig. 1). All the included studies
had a low risk of bias in random sequence generation.
Adequate methods for allocation of women were used in
all six of the RCTs. Blinding was considered difficult
methodologically given the intervention, and only one
study used a masked ST waveform analysis fetal heart
rate monitor to achieve blinding.12 Blinding the asses-
sors to the outcome was adequate in all trials. Appendix
2, available online at http://links.lww.com/AOG/A739,
shows the funnel plot for the primary outcome for as-
sessing publication bias; the symmetric plot suggests no
publication bias. Publication bias, assessed using Begg’s
and Egger’s tests, showed no significant bias (P5.39 and
P5.33, respectively).
All studies enrolled only singleton gestations with
cephalic presentation in active labor and excluded
women with multiple pregnancy or with noncephalic
position (Tables 1 and 2).7–12 One trial was signifi-
cantly different from the others regarding inclusion
criteria: the French RCT included only women with
abnormal cardiotocography in labor and excluded
normal cardiotocography cases and cardiotocography
with no decelerations.10 The inclusion of women with
pathologic cardiotocography at startup of the ST
waveform analysis in the French RCT deviated from
the ST waveform analysis clinical guidelines.15 Three
RCTs included high-risk cephalic singletons in labor
who needed continuous cardiotocography (ie, high-
risk pregnancy: pre-existing maternal disease, compli-
cated obstetric history, hypertensive disorders, intra-
uterine growth restriction, ruptured membranes for
more than 24 hours, postdate gestational age, failure
to progress, need for pain relief, meconium-stained
amniotic fluid, or nonreassuring fetal heart rate at
intermittent auscultation by a midwife),7,8,11 whereas
the other two included all cephalic singletons in labor
(ie, both high-risk and low-risk pregnancies).9,12
In all included studies all participating clinical care
providers and research personnel were trained in the
correct use of ST waveform analysis. One trial included
a 100-case test period before enrollment8; the Swedish
RCT required a 2-month practice period before enroll-
ment started and there was retraining during the trial7;
the Dutch RCT required certification and a 2-month
practice period before enrollment started11; the Amer-
ican trial required a 50-case test period, four levels of
training as well as three levels of certification12; the
other two RCTs offered some form of pretrial training
but the time was not reported.9,10 An interim analysis
was performed in all but two RCTs.9,10
Fig. 1. Assessment of risk of bias. A. Summary of risk of bias for each trial. Plus sign, low risk of bias; minus sign, high risk of
bias; question mark, unclear risk of bias. B. Risk of bias graph about each risk of bias item presented as percentages across all
included studies.
Saccone. Cardiotocography and ST Analysis. Obstet Gynecol 2016.
VOL. 127, NO. 1, JANUARY 2016 Saccone et al Cardiotocography and ST Analysis 129
Copyright ª by The American College of Obstetricians
and Gynecologists. Published by Wolters Kluwer Health, Inc.
Unauthorized reproduction of this article is prohibited.
Protocols for management in both the cardioto-
cography and the STAN groups were well described
and followed specific guidelines based on combined
evaluation of cardiotocography and ST waveform
analysis. The ST waveform analysis guideline involved
categorization of the conventional fetal heart rate
pattern into one of the three color-coded categories
(ie, green zone, yellow zone, and red zone) (Appendix 3,
available online at http://links.lww.com/AOG/
A740).15–17 The intended use of this fetal heart rate
Table 1. Descriptive Data of the Included Trials
Reference Study Location
No. of Patients at
Randomization
Gestational Age at
Randomization
(wk) Inclusion Criteria Primary Outcome
Westgate et al,8
1993
England 2,434 (1,219/1,215) Greater than 34 High-risk laboring
women, singleton
fetus, cephalic position
Operative
deliveries
Amer-Wahlin
et al,7 2001
Sweden 5,049 (2,565/2,484) 36 or greater Laboring women,
singleton fetus,
cephalic position,
continuous CTG
needed*
Neonatal metabolic
acidosis
Ojala et al,9
2006
Finland 1,472 (733/739) 36 or greater Laboring women,
singleton fetus,
cephalic position
Umbilical artery
pH less than 7.10
Vayssiere
et al,10 2007
France 799 (399/400) 36 or greater Laboring women,
singleton fetus,
cephalic position,
abnormal CTG (or thick
meconium in 7%)
Operative
deliveries
Westerhuis
et al,11 2010
The Netherlands 5,667 (2,827/2,840) 36 or greater Laboring women,
singleton fetus,
cephalic position,
continuous CTG
needed*
Neonatal metabolic
acidosis
Belfort et al,12
2015
United States 11,108 (5,532/5,576) 36 or greater Laboring women,
singleton fetus,
cephalic position,
cervical dilatation
2–7 cm
Composite
neonatal
outcome
Total — 26,529 (13,275/13,254) — — —
CTG, cardiotocography.
Data are total n (ST waveform analysis group/CTG only).
* Continuous CTG needed in pregnancies complicated by pre-existing maternal disease, complicated obstetric history, hypertensive
disorders, intrauterine growth restriction, rupture membranes for more than 24 hours, a postdate gestational age, failure to progress, need
for pain relief, meconium-stained amniotic fluid, or nonreassuring fetal heart rate at intermittent auscultation by a midwife.7,11
Fig. 2. Forest plot for the risk of the primary outcome (ie, perinatal composite outcome), that is, a composite of at least one
of the following: intrapartum fetal death, neonatal death, Apgar score of 3 or less at 5 minutes, neonatal seizure, metabolic
acidosis, intubation for ventilation at delivery, or neonatal encephalopathy. STAN, ST analysis; CTG, cardiotocography;
M-H, Mantel-Haenszel; CI, confidence interval; df, degrees of freedom.
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classification system is to suggest clinical conditions
in which adjunctive use of ST waveform changes
may aid the interpretation of specific fetal heart rate
patterns. A difference between the European RCTs
and the American RCT was that later in the use of
this technology, the European changed the three-tier
system for the STAN group to the four-tier system,
whereas Belfort et al did not follow this system since
the U.S. Food and Drug Administration had approved
the three-tier systems. Therefore, four studies use the
same protocol for ST waveform analysis (ie, four-tier
system),7,9–11 whereas in the American RCT, manage-
ment was based on a three-tier system (Appendix 3,
http://links.lww.com/AOG/A740).17 In one study, the
STAN 8801 recorder was used,8 whereas the other stud-
ies used the STAN S21, S31, or both. The S21 and the
S31 monitors provide an automatic assessment of the ST
changes and give an automatic warning in case of signif-
icant changes (fetal information was displayed on a mon-
itor and an alert was generated when the computer
detected a concerning pattern), whereas in the 8801,
the ST changes were identified by visual analysis. All
the included studies explicitly reported an intention-to-
treat analysis. Authors of one trial7 have published a re-
analysis of the study, including a correction of some
errors in the original analysis. We used the most accurate
and up-to-date data available for that trial. Only the
American RCT reported data regarding the primary out-
come. Four authors provided unpublished data from
their original trials to obtain those regarding perinatal
composite outcome (ie, primary outcome) and those
regarding the incidence of metabolic acidosis accord-
ing to the definition used in the American RCT (ie,
umbilical arterial pH 7.05 or less and extracellular
fluid base deficit 12 mmol/L or greater).7,9–11
Of the 26,529 women included in the meta-
analysis, 13,275 were randomized to the STAN group
(STAN+CTG) and 13,254 to the control group (CTG
alone) (Table 1). The STAN group had a similar inci-
dence of perinatal composite outcome: 1.5% compared
with 1.6% (RR 0.90, 95% CI 0.74–1.10; Fig. 2; Appen-
dix 3, http://links.lww.com/AOG/A740). The statistical
heterogeneity between the studies was low (I2518%).
Women who were randomized to the STAN group
had a similar rate of neonatal metabolic acidosis (0.5%
compared with 0.7%; RR 0.74, 95% CI 0.54–1.02 when
defined as umbilical arterial pH 7.05 or less and extra-
cellular fluid base deficit 12 mmol/L or greater; five
studies included; 0.7% compared with 1.0%; RR 0.81,
95% CI 0.44–1.46 when defined as umbilical arterial pH
less than 7.05 and extracellular fluid base deficit greater
than 12 mmol/L; five studies included), admission to the
neonatal intensive care unit (5.4% compared with 5.5%;
RR 0.99, 95% CI 0.90–1.10; six studies), perinatal death
(0.1% compared with 0.1%; RR 1.71, 95% CI 0.67–4.33;
six studies), neonatal encephalopathy (0.1% compared
with 0.2%; RR 0.62, 95% CI 0.25–1.52; six studies),
meconium aspiration syndrome (0.4% compared with
0.3%; RR 1.01, 95% CI 0.54–1.87; one study), and
shoulder dystocia (2.5% compared with 2.8%; RR
0.90, 95% CI 0.72–1.13; one study) (Appendix 3,
http://links.lww.com/AOG/A740, and Appendix 4,
available online at http://links.lww.com/AOG/A741).
All included RCTs, except one in which this procedure
was not used in either group,12 reported the number of
individuals who had fetal scalp blood samples taken but
Table 2. Characteristics of the Included Trials
Reference
No. of
Centers
Months
of Study
STAN
Model Used Prestudy Training Interim Analysis
STAN Guidelines
for Intervention
Westgate
et al,8 1993
1 18 8801 Yes, with 100 cases Yes, after 1,200 cases 4-tier system
Amer-Wahlin
et al,7 2001
3 18 S21* Yes, during 2 mo,
certification of users
Yes, after 1,600 cases 4-tier system
Ojala et al,9
2006
1 14 S21* Yes, but time not
reported
No information 4-tier system
Vayssiere
et al,10 2007
2 27 S21* Yes, but time not
reported
Not planned 4-tier system
Westerhuis
et al,11 2010
9 30 S21 and S31* Yes, at least 2 mo,
certification of users
Serious events monitored
by Safety Committee
4-tier system
Belfort et al,12
2015
26 48 S31* Yes, during 7 mo, 50
cases, certification
of users
Yes, but time not reported;
serious events
monitored by Safety
Committee
3-tier system
STAN, ST analysis.
* STAN S21 and S31, automatic warning monitor.7,9–12
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no information was available regarding the number of
times samples were taken from the same individual. In
four studies, the indication for a fetal blood sample was
described as optional or at a doctor’s judgment.7–10 In
one trial, three indications for fetal blood samples were
defined in the STAN group: abnormal cardiotocography
at the start of a ST waveform analysis recording, tiny
electrocardiographic signal (ie, poor electrocardiographic
signal quality defined as absence of ST information for
more than 4 minutes or less than one average electrocar-
diographic complex per minute), or more than 1 hour of
abnormal cardiotocography without the ST waveform
analysis.11 For the control group the fetal blood samples
were taken after a short period of abnormal tracing. The
incidence of fetal blood sampling was significantly lower
in the STAN group compared with the control group
(8.3% compared with 17.2%; RR 0.59, 95% CI 0.45–0.
79; five studies; Appendix 5, available online at http://
links.lww.com/AOG/A742). Nevertheless, the statisti-
cal heterogeneity within the studies was high
(I2591%) (Table 3). Regarding type of delivery, no sig-
nificant difference was found in the incidence of cesar-
ean delivery (13.8% compared with 14.0%; RR 0.96,
95% CI 0.85–1.08; six studies) or operative delivery
(either cesarean delivery or operative vaginal delivery)
(23.9% compared with 25.1%; RR 0.93, 95% CI 0.86–1.
01; six studies), whereas the incidence of operative vag-
inal delivery (either forceps or vacuum) was signifi-
cantly lower in the STAN group compared with the
control group (10.1% compared with 11.1%; RR 0.91,
95% CI 0.85–0.98; six studies) (Table 4; Appendix 6,
available online at http://links.lww.com/AOG/A743).
The statistical heterogeneity within the RCTs was
low (I2 less than 50%) for most of the secondary out-
comes (Tables 3 and 4). Appendix 7, available online at
http://links.lww.com/AOG/A744, shows the funnel
plot for the outcomes; the symmetric plots suggest no
publication bias.
The STAN group had a similar incidence of the
primary outcome (ie, perinatal composite outcome)
compared with the control group in subgroup analysis
of trials that used the automatic ST waveform analysis
(ie, STAN S21, S31, or both) (RR 0.94, 95% CI 0.75–
1.19),7,9–12 in subgroup analysis of trials in which
normal cardiotocography cases were not excluded
(RR 0.92, 95% CI 0.75–1.14),7,9,11,12 in subgroup analysis
of trials in which women were randomized at 36 weeks
of gestation or greater (RR 0.94, 95% CI 0.75–1.19),7,9–12
in subgroup analysis of trials including only high-risk
singleton gestations (RR 0.73, 95% CI 0.53–1.00),7,11 in
subgroup analysis of trials including all cephalic laboring
singleton gestations (RR 1.14, 95% CI 0.85–1.53),9,12 in
Table 3. Primary and Secondary Outcomes
Reference
Composite Perinatal
Outcome
Neonatal Metabolic
Acidosis*
Neonatal Metabolic
Acidosis† NICU
Westgate et al,8 1993 N/R N/R 5/1,219 (0.4) vs
13/1,215 (1.1)
24/1,219 (2.0) vs
31/1,215 (2.6)
Amer-Wahlin et al,7
2001
29/2,565 (1.1) vs
46/2,484 (1.9)
25/2,565 (1.0) vs
38/2,484 (1.5)
12/2,519 (0.5) vs
24/2,447 (1.0)
132/2,519 (5.2) vs
151/2,447 (6.2)
Ojala et al,9 2006 11/733 (1.5) vs
12/739 (1.6)
6/733 (0.8) vs 4/739 (0.5) 12/714 (1.7) vs
5/722 (0.7)
26/714 (3.6) vs
26/722 (3.6)
Vayssiere et al,10
2007
15/399 (3.8) vs
17/400 (4.3)
11/399 (2.8) vs
9/400 (2.3)
8/399 (2.0) 5/400 (1.3) 5/399 (1.3) vs
6/400 (1.3)
Westerhuis et al,11
2010
41/2,827 (1.5) vs
49/2,840 (1.7)
20/2,827 (0.7) vs
28/2,840 (1.0)
20/2,827 (0.7) vs
30/2,840 (1.1)
40/2,827 (1.4) vs
45/2,840 (1.6)
Belfort et al,12 2015 79/5,532 (1.4) vs
70/5,576 (1.3)
3/5,532 (0.1) vs
8/5,576 (0.1)
N/R 498/5,532 (9.0) vs
470/5,576 (8.4)
Total 175/12,056 (1.5) vs
194/12,039 (1.6)
65/12,056 (0.5) vs
87/12,039 (0.7)
57/7,678 (0.7) vs
77/7,624 (1.0)
725/13,210 (5.4) vs
729/13,200 (5.5)
I2 (%) 18 0 60 0
Method used M-H, fixed M-H, fixed M-H, random M-H, fixed
RR (95% CI) 0.90 (0.74–1.10) 0.74 (0.54–1.02) 0.81 (0.44–1.46) 0.99 (0.90–1.10)
NICU, admission to neonatal intensive care unit; N/R, not reported; N/P, not performed; N/A, not applicable; M-H, Mantel-Haenszel test;
RR, relative risk; CI, confidence interval.
Data are n ST waveform analysis group vs n cardiotocography-only group with percentage unless otherwise sepecified.
Composite perinatal outcome, a composite of at least one of: intrapartum fetal death, neonatal death, Apgar score 3 or less at 5 minutes,
neonatal seizure, metabolic acidosis (ie, umbilical arterial pH 7.05 or less and extracellular fluid base deficit 12 mmol/L or greater),
intubation for ventilation at delivery, or neonatal encephalopathy.
Bold indicates statistical significance.
* Neonatal metabolic acidosis defined as umbilical arterial pH 7.05 or less and extracellular fluid base deficit 12 mmol/L or greater.
† Neonatal metabolic acidosis defined as umbilical arterial pH less than 7.05 and extracellular fluid base deficit greater than 12 mmol/L.
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subgroup analysis of trials that enrolled only abnormal
cardiotocography cases (RR 0.88, 95% CI 0.45–1.75),10
and in subgroup analysis of trials which used the four-
tier system for the ST waveform an analysis arm (RR
0.79, 95% CI 0.61–1.03).7,9–11
DISCUSSION
This meta-analysis from six high-quality and carefully
conducted RCTs, including more than 26,000 single-
ton gestations, evaluating the effectiveness of standard
cardiotocography alone and with additional ST wave-
form analysis during labor, showed that ST waveform
analysis+cardiotocography did not improve perinatal
outcomes compared with cardiotocography alone.
Pooled results showed a positive effect of ST wave-
form analysis on reducing the need for operative vag-
inal delivery (either forceps or vacuum) and fetal
blood sampling, a procedure rarely performed in the
United States and itself of unproved value.18 Although
statistically significant, the clinical effect of a 9%
decrease in operative vaginal delivery is unclear. Fur-
thermore, in the largest trial, the U.S. study of Belfort
et al, rates of operative vaginal delivery were 5.9%
with and without ST waveform analysis.12
Our meta-analysis included appropriately pow-
ered, large-scale, well-designed high-quality RCTs.
Test of heterogeneity and sensitivity analyses all
point to the noneffectiveness of ST waveform anal-
ysis. Our findings showed that ST waveform analysis
during labor as an adjunct to cardiotocography did
not improve perinatal outcomes either in trials in
which continuous cardiotocography was routinely
used or in trials in which continuous cardiotocog-
raphy was used only in case of high-risk pregnancy.
Our results are therefore broadly generalizable.
Six other reviews have evaluated the efficacy of ST
waveform analysis+cardiotocography compared with
cardiotocography alone.19–24 However, these prior
meta-analyses did not include all currently available
RCTs, in particular the latest and largest one,12 and
therefore had a smaller number of randomized women
included.
Our study has several strengths. This meta-analysis
included all studies published so far on the topic, studies
of high quality and with a low risk of bias according to
the Cochrane risk of bias tools. The number of
randomized women was very high. To our knowledge,
no prior meta-analysis on this issue is as large, up-to-
date, or comprehensive. We assessed the primary
Perinatal Death
Neonatal
Encephalopathy
Meconium Aspiration
Syndrome Shoulder Dystocia
Fetal Blood
Sampling
2/1,219 (0.2) vs
0/1,215
1/1,219 (0.1) vs
4/1,215 (0.3)
N/R N/R 93/1,219 (7.6) vs
114/1,215 (9.4)
3/2,519 (0.1) vs
2/2,447 (0.1)
0/2,519 vs
6/2,447 (0.3)
N/R N/R 234/2,519 (9.3) vs
261/2,447 (10.7)
0/714 vs 0/722 0/714 vs 1/722 (0.1) N/R N/R 51/733 (7.0) vs
115/739 (15.6)
0/399 vs
1/400 (0.3)
1/399 (0.3) vs 1/400 (0.3) N/R N/R 108/399 (27.0) vs
248/400 (62.0)
3/2,827 (0.1) vs
2/2,840 (0.1)
3/2,827 (0.1) vs
1/2,840 (0.1)
N/R N/R 301/2,827 (10.6) vs
578/2,840 (20.4)
3/5,532 (0.1) vs
1/5,576 (0.1)
4/5,532 (0.1) vs
5/5,576 (0.1)
20/5,532 (0.4) vs
20/5,576 (0.3)
140/5,532 (2.5) vs
158/5,576 (2.8)
N/P
11/13,210 (0.1) vs
6/13,200 (0.1)
9/13,210 (0.1) vs
18/13,200 (0.2)
20/5,532 (0.4) vs
20/5,576 (0.3)
140/5,532 (2.5) vs
158/5,576 (2.8)
787/9,483 (8.3) vs
1,316/7,641 (17.2)
0 4 N/A N/A 91
M-H, fixed M-H, fixed M-H, fixed M-H, fixed M-H, Random
1.71 (0.67–4.33) 0.62 (0.25–1.52) 1.01 (0.54–1.87) 0.90 (0.72–1.13) 0.59 (0.45–0.79)
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outcome in several sensitivity analyses to reduce the
clinical heterogeneity between the trials (eg, inclusion
criteria). The statistical heterogeneity within the studies
in the primary outcome and in most of the secondary
outcomes was low (I2 less than 50%).
Limitations of our study are inherent to the
limitations of the included RCTs. Only one trial was
double-blind. Although four authors kindly provided
unpublished data from their trials, we did not have
access to all the original databases and so individual
patient-level meta-analysis was not feasible. Neonatal
encephalopathy was not uniformly defined: two RCTs
defined this outcome using the same diagnostic
criteria (ie, Sarnat and Sarnat criteria stage 1–3)25;
the American trial used the new criteria by Shankaran
et al.26 Base deficit was usually calculated in the extra-
cellular fluid compartment using the Siggaard-
Andersen algorithm, whereas the Finnish RCT re-
ported only data regarding blood base deficit. We
could not obtain data regarding composite perinatal
outcome (ie, primary outcome) and regarding inci-
dence of metabolic acidosis from Westgate et al.8 The
American RCT, which is the largest trial, had an inci-
dence of metabolic acidosis lower than the other RCTs
possibly resulting from the higher number of low risk
pregnancies included12; this issue raises the question of
the methodologic differences between the included
studies. Indeed, most trials included only women with
either abnormal cardiotocography or meconium,10 or
only high-risk pregnancies,7,8,11 so women at higher
risk for abnormal perinatal outcome and neonatal met-
abolic acidosis (Table 1). Instead, the two other trials9,12
did not select for this higher risk population and there-
fore included lower risk pregnancies.
In conclusion, our findings provide high-quality
evidence that use of ST waveform analysis during
labor as an adjunct to the standard electronic fetal
monitoring does not improve perinatal outcomes or
decrease cesarean delivery rates.
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